— Published Date: 5/13/2025
Value Proposition: A novel approach to repurposing FDA-approved anti-epileptic drugs to treat brain and nerve tumors associated with neurofibromatosis type I, offering a faster, cost-effective pathway to address an urgent unmet medical need.
Technology Description
Neuro…
— This mouse strain was designed to harbor a specific NF1 patient germline NF1 gene mutation.
— Using a series of Nf1 genetically-engineered mouse strains, researchers isolated low-grade glioma stem cells (CD133+ cells) for in vitro and in vivo brain tumor studies. These lines are authenticated optic glioma stem cells, with the ability to self-renew at limiting dilutions; express stem cell mar…
— Technology Description
Scientists at the Washington University Neurofibromatosis Center have developed a patented, first-in-class method for treating neurofibromatosis type 1 (NF1) with small molecule inhibitors of targets in the mTOR (mammalian target of rapamycin) signaling pathway. NF1 is a rel…
— Background: Neurofibromatosis type 1 (NF1) is a common neurological condition affecting roughly 1 in every 2,500 individuals. NF1 is associated with a host of clinical presentations, including malignant tumors and cognitive defects ranging from attention deficits, mental retardation, and autism. The…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
